

Christelle Mazuet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1254256/publications.pdf>

Version: 2024-02-01

46
papers

1,340
citations

331670

21
h-index

361022

35
g-index

52
all docs

52
docs citations

52
times ranked

1140
citing authors

#	ARTICLE	IF	CITATIONS
1	Closing Clostridium botulinum Group III Genomes Using Long-Read Sequencing. Microbiology Resource Announcements, 2021, 10, e0136420.	0.6	2
2	Development of An Innovative and Quick Method for the Isolation of Clostridium botulinum Strains Involved in Avian Botulism Outbreaks. Toxins, 2020, 12, 42.	3.4	9
3	A Case Report of a Botulism Outbreak in Beef Cattle Due to the Contamination of Wheat by a Roaming Cat Carcass: From the Suspicion to the Management of the Outbreak. Animals, 2019, 9, 1025.	2.3	9
4	Botulinum neurotoxin type B uses a distinct entry pathway mediated by CDC42 into intestinal cells versus neuronal cells. Cellular Microbiology, 2017, 19, e12738.	2.1	11
5	Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature. Toxins, 2017, 9, 38.	3.4	232
6	The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies. Toxins, 2017, 9, 309.	3.4	30
7	Characterization of Clostridium Baratii Type F Strains Responsible for an Outbreak of Botulism Linked to Beef Meat Consumption in France. PLOS Currents, 2017, 9, .	1.4	11
8	Translocation and dissemination to target neurons of botulinum neurotoxin type B in the mouse intestinal wall. Cellular Microbiology, 2016, 18, 282-301.	2.1	12
9	An optical biosensor assay for rapid dual detection of Botulinum neurotoxins A and E. Scientific Reports, 2016, 5, 17953.	3.3	18
10	Diversity of Group I and II Clostridium botulinum Strains from France Including Recently Identified Subtypes. Genome Biology and Evolution, 2016, 8, 1643-1660.	2.5	28
11	Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B. PLoS ONE, 2016, 11, e0161446.	2.5	21
12	A cluster of three cases of botulism due to Clostridium baratii type F, France, August 2015. Eurosurveillance, 2016, 21, .	7.0	17
13	Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain. BMC Biotechnology, 2015, 15, 86.	3.3	9
14	Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E. PLoS ONE, 2015, 10, e0139905.	2.5	21
15	A <i>vanG</i> -type locus in <i>Clostridium argentinense</i> . Journal of Antimicrobial Chemotherapy, 2015, 70, 1942-1945.	3.0	6
16	An Atypical Outbreak of Food-Borne Botulism Due to Clostridium botulinum Types B and E from Ham. Journal of Clinical Microbiology, 2015, 53, 722-726.	3.9	28
17	Characterization of botulinum neurotoxin type A subtypes by immunocapture enrichment and liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2015, 407, 5559-5570.	3.7	20
18	Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B. MAbs, 2015, 7, 1161-1177.	5.2	25

#	ARTICLE	IF	CITATIONS
19	Draft Genome Sequence of Clostridium botulinum Strain 277-00 Type B2. Genome Announcements, 2015, 3, .	0.8	1
20	Residues involved in the pore-forming activity of the <i>Clostridium perfringens</i> iota toxin. Cellular Microbiology, 2015, 17, 288-302.	2.1	23
21	Clostridium botulinum. , 2014, , 185-212.		9
22	An Atypical Clostridium Strain Related to the Clostridium botulinum Group III Strain Isolated from a Human Blood Culture. Journal of Clinical Microbiology, 2014, 52, 339-343.	3.9	3
23	Direct biosensor detection of botulinum neurotoxin endopeptidase activity in sera from patients with type A botulism. Biosensors and Bioelectronics, 2014, 57, 207-212.	10.1	19
24	Regulation of toxin synthesis in Clostridium botulinum and Clostridium tetani. Toxicon, 2013, 75, 90-100.	1.6	24
25	Characterization of different subtypes of botulinum type A toxins by mass spectrometry. Toxicon, 2013, 75, 221.	1.6	0
26	Botulism and Tetanus. , 2013, , 247-290.		6
27	DNA electroporation in rabbits as a method for generation of high-titer neutralizing antisera. Human Vaccines and Immunotherapeutics, 2013, 9, 2147-2156.	3.3	4
28	Application of High-Density DNA Resequencing Microarray for Detection and Characterization of Botulinum Neurotoxin-Producing Clostridia. PLoS ONE, 2013, 8, e67510.	2.5	23
29	Toxin Detection in Patients' Sera by Mass Spectrometry during Two Outbreaks of Type A Botulism in France. Journal of Clinical Microbiology, 2012, 50, 4091-4094.	3.9	27
30	Two-Component Systems Are Involved in the Regulation of Botulinum Neurotoxin Synthesis in Clostridium botulinum Type A Strain Hall. PLoS ONE, 2012, 7, e41848.	2.5	24
31	Two cases of type A infant botulism in Grenoble, France: no honey for infants. European Journal of Pediatrics, 2012, 171, 589-591.	2.7	11
32	A label-free biosensor assay for botulinum neurotoxin B in food and human serum. Analytical Biochemistry, 2011, 410, 281-288.	2.4	39
33	Characterization of Botulinum Neurotoxin Type A Neutralizing Monoclonal Antibodies and Influence of Their Half-Lives on Therapeutic Activity. PLoS ONE, 2010, 5, e12416.	2.5	33
34	Production and Characterisation of a Neutralising Chimeric Antibody against Botulinum Neurotoxin A. PLoS ONE, 2010, 5, e13245.	2.5	11
35	Development of real-time PCR tests for detecting botulinum neurotoxins A, B, E, F producing <i>Clostridium botulinum</i> , <i>Clostridium baratii</i> and <i>Clostridium butyricum</i> . Journal of Applied Microbiology, 2009, 107, 465-473.	3.1	70
36	Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D. Vaccine, 2009, 27, 5661-5666.	3.8	18

#	ARTICLE	IF	CITATIONS
37	A sensitive sandwich enzyme immunoassay for free or complexed Clostridium botulinum neurotoxin type A. Journal of Immunological Methods, 2008, 330, 120-129.	1.4	28
38	Clostridium sordellii Lethal Toxin Kills Mice by Inducing a Major Increase in Lung Vascular Permeability. American Journal of Pathology, 2007, 170, 1003-1017.	3.8	56
39	Alternative vaccination against equine botulism (BoNT/C). Equine Veterinary Journal, 2007, 39, 516-520.	1.7	11
40	A new and simple method used as cleaning system for measuring mite and cat allergens in homes. Journal of Allergy and Clinical Immunology, 2002, 109, S55-S55.	2.9	0
41	Interleukin-1 receptor antagonist production during infectious and noninfectious systemic inflammatory response syndrome. Critical Care Medicine, 2000, 28, 2277-2282.	0.9	54
42	INTERLEUKIN 8 PRODUCTION IN WHOLE BLOOD ASSAYS: IS INTERLEUKIN 10 RESPONSIBLE FOR THE DOWNREGULATION OBSERVED IN SEPSIS?. Cytokine, 2000, 12, 55-61.	3.2	32
43	Paradoxical priming effects of IL-10 on cytokine production. International Immunology, 1999, 11, 689-698.	4.0	34
44	Cytokines and Soluble Cytokine Receptors in Pleural Effusions from Septic and Nonseptic Patients. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1515-1522.	5.6	59
45	IL-10 and IL-4 synergize with TNF- α to induce IL-1ra production by human neutrophils. Cytokine, 1996, 8, 147-151.	3.2	67
46	Regulation by anti-inflammatory cytokines (IL-4, IL-10, IL-13, TGF β ²) of interleukin-8 production by LPS- and/ or TNF α -activated human polymorphonuclear cells. Mediators of Inflammation, 1996, 5, 334-340.	3.0	72